Abstract
BackgroundTransgenic overexpression of apolipoprotein A-I (apoA1) has been shown to delay atherosclerosis lesion progression and promote lesion regression in mouse models; however, apoA1 is subject to oxidation by myeloperoxidase (MPO) and loss of function. The activity of oxidant resistant human apoA1 was compared to unmodified human apoA1 in mouse models of atherosclerosis progression and regression.Methods and resultsHuman apoA1 and the MPO oxidant resistant 4WF isoform transgenic mice were bred to LDL receptor deficient (LDLr KO) mice and fed a western-type diet. High level expression of these human apoA1 isoforms did not lead to increased HDL-cholesterol levels on the LDLr KO background. In males and females, lesion progression was studied over time, and both apoA1 and 4WF transgenic mice vs. LDLr KO mice had significant and similar delayed lesion progression and reduced non-HDL cholesterol. Using time points with equivalent lesion areas, lesion regression was initiated by feeding the mice a low-fat control diet containing a microsomal triglyceride transfer protein inhibitor for 7 weeks. Lesions regressed more in the male apoA1 and 4WF transgenics vs. the LDLr KO, but the 4WF isoform was not superior to the unmodified isoform in promoting lesion regression.ConclusionsBoth human apoA1 and the 4WF MPO oxidant resistant apoA1 isoform delayed lesion progression and promoted lesion regression in LDLr KO mice, with more pronounced effects in males than females; moreover, the 4WF isoform functioned similarly to the unmodified human apoA1 isoform.
Highlights
Low levels of HDL-C do not appear to be directly causal for atherosclerosis in humans based on mendelian randomization genetic analysis [1]
Cleveland Clinic is an inventor for a patent (US8536117B2) entitled "Oxidant resistant apolipoprotein A-1 and mimetic peptides
Upon ex-vivo modification of HDL from these two transgenic lines, we demonstrated that the wild type human apoA1 containing HDL loses all of its ABCA1-dependent cholesterol acceptor activity, while the 4WF containing HDL is partially resistant to MPO mediated loss of ABCA1-dependent cholesterol acceptor activity [13]
Summary
Low levels of HDL-C do not appear to be directly causal for atherosclerosis in humans based on mendelian randomization genetic analysis [1]. One well-studied mechanism for HDL’s loss of function is through its oxidation by myeloperoxidase (MPO) [7], with about 1 in 5 HDL molecules recovered from human atheroma bearing the signature of this modification [8]. Transgenic overexpression of apolipoprotein A-I (apoA1) has been shown to delay atherosclerosis lesion progression and promote lesion regression in mouse models; apoA1 is subject to oxidation by myeloperoxidase (MPO) and loss of function. The activity of oxidant resistant human apoA1 was compared to unmodified human apoA1 in mouse models of atherosclerosis progression and regression
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.